| _version_ |
1860797477162057728
|
| building |
INTELEK Repository
|
| caption |
Pain and Therapy, doi:10.1007/s40122-016-0044-3
|
| collection |
Online Access
|
| collectionurl |
https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072
|
| date |
2024-08-27 14:42:27
|
| format |
Restricted Document
|
| id |
12887
|
| institution |
UniSZA
|
| internalnotes |
1. Hsu W-Y, Chiu N-Y, Liu J-T, et al. Sleep quality in heroin addicts under methadone maintenance treatment. Acta Neuropsychiatr. 2012;24(6):356–60. 2. Liao Y, Tang J, Liu T, Chen X, Luo T, Hao W. Sleeping problems among Chinese heroin-dependent individuals. Am J Drug Alcohol Abuse. 2011;37(3):179–83. 3. Peles E, Schreiber S, Adelson M. Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients. Drug Alcohol Depend. 2006;82(2):103–10. 4. Peles E, Schreiber S, Adelson M. Documented poor sleep among methadone-maintained patients is associated with chronic pain and benzodiazepine abuse, but not with methadone dose. Eur Neuropsychopharmacol. 2009;19(8):581–8. 5. Pud D, Zlotnick C, Lawental E. Pain depression and sleep disorders among methadone maintenance treatment patients. Addict Behav. 2012;37(11):1205–10. 6. Stein MD, Herman DS, Bishop S, et al. Sleep disturbances among methadone maintained patients. J Subst Abuse Treat. 2004;26(3):175–80. 7. Wang D, Teichtahl H, Drummer O, et al. Central sleep apnea in stable methadone maintenance treatment patients. Chest. 2005;128(3):1348–56. 8. Wang D, Teichtahl H, Goodman C, Drummer O, Grunstein RR, Kronborg I. Subjective daytime sleepiness and daytime function in patients on stable methadone maintenance treatment: possible mechanisms. J Clin Sleep Med. 2008;4(6):557–62. 9. Beswick T, Best D, Rees S, Bearn J, Gossop M, Strang J. Major disruptions of sleep during treatment of the opiate withdrawal syndrome: differences between methadone and lofexidine detoxification treatments. Addict Biol. 2003;8(1):49–57. 10. Gossop M, Bradley B. Insomnia among addicts during supervised withdrawal from opiates: a comparison of oral methadone and electrostimulation. Drug Alcohol Depend. 1984;13(2):191–8. 11. Oyefeso A, Sedgwick P, Ghodse H. Subjective sleep-wake parameters in treatment-seeking opiate addicts. Drug Alcohol Depend. 1997;48(1):9–16. 12. Staedt J, Wassmuth F, Stoppe G, et al. Effects of chronic treatment with methadone and naltrexone on sleep in addicts. Eur Arch Psychiatry Clin Neurosci. 1996;246(6):305–9. 13. Moore JT, Kelz MB. Opiates, sleep, and pain: the adenosinergic link. Anesthesiology. 2009;111(6):1175–6. 14. Nelson AM, Battersby AS, Baghdoyan HA, Lydic R. Opioid-induced decreases in rat brain adenosine levels are reversed by inhibiting adenosine deaminase. Anesthesiology. 2009;111(6):1327–33. 15. Klepstad P, Rakvag TT, Kaasa S, et al. The 118 A[G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48(10):1232–9. 16. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem. 2001;276(5):3130–7. 17. Ravindranathan A, Joslyn G, Robertson M, Schuckit MA, Whistler JL, White RL. Functional characterization of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci USA. 2009;106(26):10811–6. 18. Huang P, Chen C, Mague SD, Blendy JA, Liu-Chen LY. A common single nucleotide polymorphism A118G of the mu opioid receptor alters its N-glycosylation and protein stability. Biochem J. 2012;441(1):379–86. 19. Xin L, Wang ZJ. Bioinformatic analysis of the human mu opioid receptor (OPRM1) splice and polymorphic variants. AAPS PharmSci. 2002;4(4):E23. 20. Hoehe MR, Kopke K, Wendel B, et al. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet. 2000;9(19):2895–908. 21. Lotsch J, Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J. 2006;6(3):200–10. 22. Wendel B, Hoehe MR. The human mu opioid receptor gene: 50 regulatory and intronic sequences. J Mol Med (Berl). 1998;76(7):525–32. 23. Compton P, Geschwind DH, Alarcon M. Association between human mu-opioid receptor gene polymorphism, pain tolerance, and opioid addiction. Am J Med Genet B Neuropsychiatr Genet. 2003;121B(1):76–82. 24. Wang SC, Tsou HH, Chen CH, et al. Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients. Eur Neuropsychopharmacol. 2012;22(10):695–703. 25. Fonseca F, Gratacos M, Escaramis G, et al. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol Diagn Ther. 2010;14(3):171–8. 26. Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D. Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations. J Anal Toxicol. 2011;35(7):431–7. 27. Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther. 2010;88(3):383–9. 28. Zahari Z, Lee CS, Ibrahim MA, et al. The opposing roles of IVS2 ? 691 CC genotype and AC/AG diplotype of 118A[G and IVS2 ? 691G[C of OPRM1 polymorphisms in cold pain tolerance among opioid-dependent Malay males on methadone therapy. Pain Ther. 2015;4(2):179–96. 29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994. 30. Manan MM, Ali SM, Khan MA, Jafarian S, Hameed MA. Review on the demographic and social impact of methadone-medication therapy on Malaysian patients. Pak J Pharm Sci. 2013;26(4):841–6. 31. Charpentier A, Bisac S, Poirot I, Vignau J, Cottencin O. Sleep quality and apnea in stable methadone maintenance treatment. Subst Use Misuse. 2010;45(9):1431–4. 32. Kurth ME, Sharkey KM, Millman RP, Corso RP, Stein MD. Insomnia among methadone-maintained individuals: the feasibility of collecting home polysomnographic recordings. J Addict Dis. 2009;28(3):219–25. 33. Peles E, Schreiber S, Hamburger RB, Adelson M. No change of sleep after 6 and 12 months of methadone maintenance treatment. J Addict Med. 2011;5(2):141–7. 34. Sharkey KM, Kurth ME, Anderson BJ, Corso RP, Millman RP, Stein MD. Obstructive sleep apnea is more common than central sleep apnea in methadone maintenance patients with subjective sleep complaints. Drug Alcohol Depend. 2010;108(1–2):77–83. 35. Sharkey KM, Kurth ME, Anderson BJ, Corso RP, Millman RP, Stein MD. Assessing sleep in opioid dependence: a comparison of subjective ratings, sleep diaries, and home polysomnography in methadone maintenance patients. Drug Alcohol Depend. 2011;113(2–3):245–8. 36. Sharkey KM, Kurth ME, Corso RP, Brower KJ, Millman RP, Stein MD. Home polysomnography in methadone maintenance patients with subjective sleep complaints. Am J Drug Alcohol Abuse. 2009;35(3):178–82. 37. Stein MD, Kurth ME, Sharkey KM, Anderson BJ, Corso RP, Millman RP. Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial. Drug Alcohol Depend. 2012;120(1–3):65–73. 38. Zahari Z, Lee CS, Tan SC, Mohamad N, Lee YY, Ismail R. Relationship between cold pressor pain-sensitivity and sleep quality in opioid-dependent males on methadone treatment. PeerJ. 2015;3:e839. 39. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. 40. Mohamed Nazar NI. Therapeutic drug monitoring in methadone maintenance therapy (MMT): an evaluation of genetic factors influencing clinical outcomes and serum concentrations of methadone: Ph.D. Thesis, Universiti Sains Malaysia; 2013. 41. Belfer I, Segall SK, Lariviere WR, et al. Pain modality- and sex-specific effects of COMT genetic functional variants. Pain. 2013;154(8):1368–76. 42. Ding S, Chen B, Zheng Y, Lu Q, Liu L, Zhuge QC. Association study of OPRM1 polymorphisms with schizophrenia in Han Chinese population. BMC Psychiatry. 2013;13:107. 43. Hayashida M, Nagashima M, Satoh Y, et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics. 2008;9(11):1605–16. 44. Mahfoud Y, Talih F, Streem D, Budur K. Sleep disorders in substance abusers: how common are they? Psychiatry (Edgmont). 2009;6(9):38–42.
|
| originalfilename |
7195-01-FH02-FP-16-05478.pdf
|
| person |
Zalina Zahari
|
| recordtype |
oai_dc
|
| resourceurl |
https://intelek.unisza.edu.my/intelek/pages/view.php?ref=12887
|
| spelling |
12887 https://intelek.unisza.edu.my/intelek/pages/view.php?ref=12887 https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072 Restricted Document Article Journal application/pdf Adobe Acrobat Pro DC 20 Paper Capture Plug-in with ClearScan 13 1.6 Zalina Zahari 2024-08-27 14:42:27 Pain and Therapy, doi:10.1007/s40122-016-0044-3 Pain and Therapy doi:10.1007/s40122-016-0044-3 7195-01-FH02-FP-16-05478.pdf UniSZA Private Access The AC/AG Diplotype for the 118A>G and IVS2 + 691G>C Polymorphisms of OPRM1 Gene is Associated with Sleep Quality Among OpioidDependent Patients on Methadone Maintenance Therapy Pain and Therapy Introduction Methadone is a full agonist of the opioid receptor mu 1 which is encoded by the OPRM1 gene. Sleep disorders were frequently reported by opioid-dependent patients during methadone maintenance therapy (MMT). It is possible, therefore, that genetic polymorphisms in OPRM1 influence sleep quality among patients on MMT. This study investigated the association of OPRM1 polymorphisms with sleep quality among opioid-dependent patients on MMT. Methods The sleep quality of 165 male opioid-dependent patients receiving MMT was evaluated using the Pittsburgh Sleep Quality Index (PSQI). DNA was extracted from whole blood and subjected to polymerase chain reaction (PCR) genotyping. Results Patients with IVS2 + 691 CC genotype had higher PSQI scores [mean (SD) = 5.73 (2.89)] compared to those without the IVS2 + 691 CC genotype (IVS2 + 691 GG/GC genotype) [4.92 (2.31)], but the difference did not reach statistical significance (p = 0.081). Patients with combined 118 AA genotype and IVS2 + 691 GC genotype (AC/AG diplotype) had significantly lower PSQI scores [mean (SD) = 4.25 (2.27)] compared to those without the diplotype [5.68 (2.77)] (p = 0.018). Conclusion Our study indicates that the AC/AG diplotype for the 118A>G and IVS2 + 691G>C polymorphisms of OPRM1 gene is associated with better sleep quality among males with opioid dependence on MMT. 5 1 1. Hsu W-Y, Chiu N-Y, Liu J-T, et al. Sleep quality in heroin addicts under methadone maintenance treatment. Acta Neuropsychiatr. 2012;24(6):356–60. 2. Liao Y, Tang J, Liu T, Chen X, Luo T, Hao W. Sleeping problems among Chinese heroin-dependent individuals. Am J Drug Alcohol Abuse. 2011;37(3):179–83. 3. Peles E, Schreiber S, Adelson M. Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients. Drug Alcohol Depend. 2006;82(2):103–10. 4. Peles E, Schreiber S, Adelson M. Documented poor sleep among methadone-maintained patients is associated with chronic pain and benzodiazepine abuse, but not with methadone dose. Eur Neuropsychopharmacol. 2009;19(8):581–8. 5. Pud D, Zlotnick C, Lawental E. Pain depression and sleep disorders among methadone maintenance treatment patients. Addict Behav. 2012;37(11):1205–10. 6. Stein MD, Herman DS, Bishop S, et al. Sleep disturbances among methadone maintained patients. J Subst Abuse Treat. 2004;26(3):175–80. 7. Wang D, Teichtahl H, Drummer O, et al. Central sleep apnea in stable methadone maintenance treatment patients. Chest. 2005;128(3):1348–56. 8. Wang D, Teichtahl H, Goodman C, Drummer O, Grunstein RR, Kronborg I. Subjective daytime sleepiness and daytime function in patients on stable methadone maintenance treatment: possible mechanisms. J Clin Sleep Med. 2008;4(6):557–62. 9. Beswick T, Best D, Rees S, Bearn J, Gossop M, Strang J. Major disruptions of sleep during treatment of the opiate withdrawal syndrome: differences between methadone and lofexidine detoxification treatments. Addict Biol. 2003;8(1):49–57. 10. Gossop M, Bradley B. Insomnia among addicts during supervised withdrawal from opiates: a comparison of oral methadone and electrostimulation. Drug Alcohol Depend. 1984;13(2):191–8. 11. Oyefeso A, Sedgwick P, Ghodse H. Subjective sleep-wake parameters in treatment-seeking opiate addicts. Drug Alcohol Depend. 1997;48(1):9–16. 12. Staedt J, Wassmuth F, Stoppe G, et al. Effects of chronic treatment with methadone and naltrexone on sleep in addicts. Eur Arch Psychiatry Clin Neurosci. 1996;246(6):305–9. 13. Moore JT, Kelz MB. Opiates, sleep, and pain: the adenosinergic link. Anesthesiology. 2009;111(6):1175–6. 14. Nelson AM, Battersby AS, Baghdoyan HA, Lydic R. Opioid-induced decreases in rat brain adenosine levels are reversed by inhibiting adenosine deaminase. Anesthesiology. 2009;111(6):1327–33. 15. Klepstad P, Rakvag TT, Kaasa S, et al. The 118 A[G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48(10):1232–9. 16. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem. 2001;276(5):3130–7. 17. Ravindranathan A, Joslyn G, Robertson M, Schuckit MA, Whistler JL, White RL. Functional characterization of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci USA. 2009;106(26):10811–6. 18. Huang P, Chen C, Mague SD, Blendy JA, Liu-Chen LY. A common single nucleotide polymorphism A118G of the mu opioid receptor alters its N-glycosylation and protein stability. Biochem J. 2012;441(1):379–86. 19. Xin L, Wang ZJ. Bioinformatic analysis of the human mu opioid receptor (OPRM1) splice and polymorphic variants. AAPS PharmSci. 2002;4(4):E23. 20. Hoehe MR, Kopke K, Wendel B, et al. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet. 2000;9(19):2895–908. 21. Lotsch J, Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J. 2006;6(3):200–10. 22. Wendel B, Hoehe MR. The human mu opioid receptor gene: 50 regulatory and intronic sequences. J Mol Med (Berl). 1998;76(7):525–32. 23. Compton P, Geschwind DH, Alarcon M. Association between human mu-opioid receptor gene polymorphism, pain tolerance, and opioid addiction. Am J Med Genet B Neuropsychiatr Genet. 2003;121B(1):76–82. 24. Wang SC, Tsou HH, Chen CH, et al. Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients. Eur Neuropsychopharmacol. 2012;22(10):695–703. 25. Fonseca F, Gratacos M, Escaramis G, et al. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol Diagn Ther. 2010;14(3):171–8. 26. Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D. Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations. J Anal Toxicol. 2011;35(7):431–7. 27. Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther. 2010;88(3):383–9. 28. Zahari Z, Lee CS, Ibrahim MA, et al. The opposing roles of IVS2 ? 691 CC genotype and AC/AG diplotype of 118A[G and IVS2 ? 691G[C of OPRM1 polymorphisms in cold pain tolerance among opioid-dependent Malay males on methadone therapy. Pain Ther. 2015;4(2):179–96. 29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994. 30. Manan MM, Ali SM, Khan MA, Jafarian S, Hameed MA. Review on the demographic and social impact of methadone-medication therapy on Malaysian patients. Pak J Pharm Sci. 2013;26(4):841–6. 31. Charpentier A, Bisac S, Poirot I, Vignau J, Cottencin O. Sleep quality and apnea in stable methadone maintenance treatment. Subst Use Misuse. 2010;45(9):1431–4. 32. Kurth ME, Sharkey KM, Millman RP, Corso RP, Stein MD. Insomnia among methadone-maintained individuals: the feasibility of collecting home polysomnographic recordings. J Addict Dis. 2009;28(3):219–25. 33. Peles E, Schreiber S, Hamburger RB, Adelson M. No change of sleep after 6 and 12 months of methadone maintenance treatment. J Addict Med. 2011;5(2):141–7. 34. Sharkey KM, Kurth ME, Anderson BJ, Corso RP, Millman RP, Stein MD. Obstructive sleep apnea is more common than central sleep apnea in methadone maintenance patients with subjective sleep complaints. Drug Alcohol Depend. 2010;108(1–2):77–83. 35. Sharkey KM, Kurth ME, Anderson BJ, Corso RP, Millman RP, Stein MD. Assessing sleep in opioid dependence: a comparison of subjective ratings, sleep diaries, and home polysomnography in methadone maintenance patients. Drug Alcohol Depend. 2011;113(2–3):245–8. 36. Sharkey KM, Kurth ME, Corso RP, Brower KJ, Millman RP, Stein MD. Home polysomnography in methadone maintenance patients with subjective sleep complaints. Am J Drug Alcohol Abuse. 2009;35(3):178–82. 37. Stein MD, Kurth ME, Sharkey KM, Anderson BJ, Corso RP, Millman RP. Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial. Drug Alcohol Depend. 2012;120(1–3):65–73. 38. Zahari Z, Lee CS, Tan SC, Mohamad N, Lee YY, Ismail R. Relationship between cold pressor pain-sensitivity and sleep quality in opioid-dependent males on methadone treatment. PeerJ. 2015;3:e839. 39. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. 40. Mohamed Nazar NI. Therapeutic drug monitoring in methadone maintenance therapy (MMT): an evaluation of genetic factors influencing clinical outcomes and serum concentrations of methadone: Ph.D. Thesis, Universiti Sains Malaysia; 2013. 41. Belfer I, Segall SK, Lariviere WR, et al. Pain modality- and sex-specific effects of COMT genetic functional variants. Pain. 2013;154(8):1368–76. 42. Ding S, Chen B, Zheng Y, Lu Q, Liu L, Zhuge QC. Association study of OPRM1 polymorphisms with schizophrenia in Han Chinese population. BMC Psychiatry. 2013;13:107. 43. Hayashida M, Nagashima M, Satoh Y, et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics. 2008;9(11):1605–16. 44. Mahfoud Y, Talih F, Streem D, Budur K. Sleep disorders in substance abusers: how common are they? Psychiatry (Edgmont). 2009;6(9):38–42.
|
| spellingShingle |
The AC/AG Diplotype for the 118A>G and IVS2 + 691G>C Polymorphisms of OPRM1 Gene is Associated with Sleep Quality Among OpioidDependent Patients on Methadone Maintenance Therapy
|
| subject |
Pain and Therapy
doi:10.1007/s40122-016-0044-3
|
| summary |
Introduction Methadone is a full agonist of the opioid receptor mu 1 which is encoded by the OPRM1 gene. Sleep disorders were frequently reported by opioid-dependent patients during methadone maintenance therapy (MMT). It is possible, therefore, that genetic polymorphisms in OPRM1 influence sleep quality among patients on MMT. This study investigated the association of OPRM1 polymorphisms with sleep quality among opioid-dependent patients on MMT. Methods The sleep quality of 165 male opioid-dependent patients receiving MMT was evaluated using the Pittsburgh Sleep Quality Index (PSQI). DNA was extracted from whole blood and subjected to polymerase chain reaction (PCR) genotyping. Results Patients with IVS2 + 691 CC genotype had higher PSQI scores [mean (SD) = 5.73 (2.89)] compared to those without the IVS2 + 691 CC genotype (IVS2 + 691 GG/GC genotype) [4.92 (2.31)], but the difference did not reach statistical significance (p = 0.081). Patients with combined 118 AA genotype and IVS2 + 691 GC genotype (AC/AG diplotype) had significantly lower PSQI scores [mean (SD) = 4.25 (2.27)] compared to those without the diplotype [5.68 (2.77)] (p = 0.018). Conclusion Our study indicates that the AC/AG diplotype for the 118A>G and IVS2 + 691G>C polymorphisms of OPRM1 gene is associated with better sleep quality among males with opioid dependence on MMT.
|
| title |
The AC/AG Diplotype for the 118A>G and IVS2 + 691G>C Polymorphisms of OPRM1 Gene is Associated with Sleep Quality Among OpioidDependent Patients on Methadone Maintenance Therapy
|
| title_full |
The AC/AG Diplotype for the 118A>G and IVS2 + 691G>C Polymorphisms of OPRM1 Gene is Associated with Sleep Quality Among OpioidDependent Patients on Methadone Maintenance Therapy
|
| title_fullStr |
The AC/AG Diplotype for the 118A>G and IVS2 + 691G>C Polymorphisms of OPRM1 Gene is Associated with Sleep Quality Among OpioidDependent Patients on Methadone Maintenance Therapy
|
| title_full_unstemmed |
The AC/AG Diplotype for the 118A>G and IVS2 + 691G>C Polymorphisms of OPRM1 Gene is Associated with Sleep Quality Among OpioidDependent Patients on Methadone Maintenance Therapy
|
| title_short |
The AC/AG Diplotype for the 118A>G and IVS2 + 691G>C Polymorphisms of OPRM1 Gene is Associated with Sleep Quality Among OpioidDependent Patients on Methadone Maintenance Therapy
|
| title_sort |
ac/ag diplotype for the 118a>g and ivs2 + 691g>c polymorphisms of oprm1 gene is associated with sleep quality among opioiddependent patients on methadone maintenance therapy
|